心肌缺血再灌注损伤的防治新靶点寻找及其研究进展  

Advance of novel target strategies participating in myocardial ischemia reperfusion injury

作　　者：侯凯 谭昊宇 刘静[1] 李运曼[3] HOU Kai;TAN Haoyu;LIU Jing;LI Yunman(Department of Pharmacy,Zhongda Hospital,Southeast University,Nanjing 210009;Cardiovascular Surgery,The Second XiangYa Hospital of Central South University,Changsha 410000;State Key Laboratory of Natural Medicines,Department of Physiology,China Pharmaceutical University,Nanjing 210009,China)

机构地区：[1]东南大学附属中大医院药学部,南京210009 [2]中南大学湘雅二医院心血管外科,长沙410000 [3]中国药科大学生理教研室,天然药物活性组分与药效国家重点实验室,南京210009

出　　处：《中国药科大学学报》2022年第2期164-170,共7页Journal of China Pharmaceutical University

基　　金：中国药科大学“双一流”建设科技创新团队项目资助(No.CPU2018GY23)。

摘　　要：急性心肌梗死(AMI)及心力衰竭并发症的发病率和病死率在全世界居高不下。经证实心肌梗死后冠状动脉的早期再灌注是典型而有效的治疗方法,但侧支和冠脉缺血再灌注损伤(MIRI)及相关心脏保护机制尚不清楚。AMI的发生机制是多因素的,它通过多种机制导致心肌细胞死亡,并影响其他类型的细胞,包括血小板、成纤维细胞、内皮细胞和平滑肌细胞以及免疫细胞。大多数心脏保护策略通过常见的终末效应物发挥作用,但在合并症患者中的效果可能并不理想。因此,研究触发和治疗MIRI病理生理学相关的多靶点防治策略有重要意义。特别关注心脏保护策略现状,以此简单阐述参与防治心肌缺血再灌注损伤的多靶点治疗组合以及在研新靶点,以期为MIRI的机制研究与新药研发提供思路。Worldwide morbidity and mortality of acute myocardial infarction(AMI)and related heart failure are still high.While effective early reperfusion of the criminal coronary artery after a confirmed AMI is the typical and effective treatment at present,collateral myocardial ischemia reperfusion injury(MIRI)and pertinent cardioprotection are still challenging to address and have inadequately understood mechanisms.One important reason might be that AMI is multifactorial,causing cardiomyocyte death via multiple mechanisms,as well as affecting other cell types,including platelets,fibroblasts,endothelial and smooth muscle cells,and immune cells.Many cardioprotective strategies act through common end-effectors and may be suboptimal in patients with comorbidities.Therefore,unveiling the related multitarget strategies participating in triggering and resisting the pathobiology of MIRI is a promising and valuable frontier.The review specifically focuses on the recent MIRI advances that are supported by multitarget strategies and new targets under development in order to bring the rational combination of multitarget therapies up to date,as well as to identify findings that may facilitate the new drug of novel targets.

关 键 词：心肌缺血 缺血再灌注损伤 多靶点 心肌保护策略 新靶点 进展 

分 类 号：R965[医药卫生—药理学]